BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

PURPOSE: Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day (D+T). PATIENTS AND METHODS: We conducted a phase I/II clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehnert, Janice M., Mitchell, Tara C., Huang, Alexander C., Aleman, Tomas S., Kim, Benjamin J., Schuchter, Lynn M., Linette, Gerald P., Karakousis, Giorgos C., Mitnick, Sheryl, Giles, Lydia, Carberry, Mary, Frey, Noelle, Kossenkov, Andrew, Groisberg, Roman, Hernandez-Aya, Leonel F., Ansstas, George, Silk, Ann W., Chandra, Sunandana, Sosman, Jeffrey A., Gimotty, Phyllis A., Mick, Rosemarie, Amaravadi, Ravi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923957/
https://www.ncbi.nlm.nih.gov/pubmed/35022320
http://dx.doi.org/10.1158/1078-0432.CCR-21-3382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923957/
https://www.ncbi.nlm.nih.gov/pubmed/35022320
http://dx.doi.org/10.1158/1078-0432.CCR-21-3382

Ejemplares similares